Загрузка...
EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
BRAF(V600E) is the most common oncogenic lesion in melanoma and results in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncogenic signaling, restrain cellular g...
Сохранить в:
| Опубликовано в: : | Cancer Discov |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4355085/ https://ncbi.nlm.nih.gov/pubmed/25542448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0295 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|